How should an intermittent rash be evaluated and managed?

Evaluation and Management of Intermittent Rash

For an intermittent rash, begin by determining if the lesions are urticarial (weals lasting 2-24 hours) versus eczematous (persistent patches), then assess for specific triggers through detailed history and consider patch testing for persistent cases or antihistamine therapy for urticaria.

Initial Classification by Morphology and Duration

The critical first step is determining what type of rash you're dealing with:

Urticarial Pattern (Weals/Hives)

• Individual lesions last 2-24 hours in ordinary urticaria 1
• Less than 1 hour in physical urticarias (except delayed pressure urticaria) 1
• Lesions are transient, migratory, and itchy
• If individual weals last >24 hours, consider urticarial vasculitis and obtain skin biopsy 2, 1

Eczematous Pattern (Contact Dermatitis)

• Lesions persist in the same location
• Characterized by erythema, vesiculation (acute phase) or dryness, lichenification, and fissuring (chronic phase) 3
• Pattern may suggest external triggers

Detailed History - Key Questions

For Urticaria:

1. Duration of individual weals: "For how long does each individual wheal last?" 4
2. Reproducible triggers: Can you make the weals appear by specific actions (rubbing skin, cold exposure, exercise, pressure)? 4
3. Timing patterns: Do symptoms improve on weekends/holidays and worsen at work? 3
4. Associated angioedema: Swelling of lips, tongue, or deeper tissues? 1
5. Systemic symptoms: Fever, joint pain, malaise (suggests autoinflammatory disease or vasculitis) 4

For Eczematous Rash:

1. Initial location and spread pattern 3
2. Product exposure: Cosmetics, personal care products, topical medications, gloves, bandages 3
3. Occupational factors: Specific work activities, products handled, improvement away from work 3
4. Atopic history: Personal or family history of eczema, asthma, hay fever 3
5. Wash products: All products contacting skin (harsh surfactants damage skin barrier) 3

Diagnostic Approach

For Suspected Urticaria:

Acute urticaria (<6 weeks):

• Minimal investigation needed if trigger obvious 1
• Consider food/drug allergy testing if suspected allergen 2

Chronic urticaria (≥6 weeks continuous activity):

• Refer to allergist-immunologist for comprehensive evaluation including possible causative factors, skin testing, physical challenges, and optimal pharmacotherapy 2
• Minimal laboratory testing recommended - extensive workups have low yield 2
• Consider autoserum skin test (ASST) for autoimmune urticaria (present in ≥30% of chronic cases) 1

Red flags requiring urgent evaluation:

• Weals lasting >24 hours with residual bruising/pigmentation (urticarial vasculitis) 2
• Recurrent fever, joint pain, malaise (systemic disease) 2
• Angioedema without weals (consider ACE inhibitor-induced or C1 esterase inhibitor deficiency) 1, 4

For Suspected Contact Dermatitis:

Offer patch testing with baseline allergen series to all patients with persistent or chronic dermatitis 3

• Clinical features alone cannot distinguish allergic from irritant or endogenous dermatitis 3
• Consider additional allergen series based on occupational/recreational exposures 3
• Readings at day 2, day 4, and consider day 6-7 if unexpectedly negative 3
• Defer patch testing 3 months after systemic agents, 6 months after biologics to avoid false negatives 3

Management Algorithm

For Urticaria:

First-line: Non-sedating H1 antihistamines

• Offer choice of at least two different agents (responses vary between individuals) 1
• Options: cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine (once daily) 1
• If inadequate response: Increase dose up to 4x manufacturer's recommendation (common practice when benefits outweigh risks) 1
• Adjust timing so peak levels coincide with anticipated symptoms 1

Second-line additions for resistant cases:

• Add H2 antihistamine (may improve control beyond H1 alone) 1
• Add sedating antihistamine at night (chlorphenamine 4-12 mg or hydroxyzine 10-50 mg) for sleep 1
• Consider antileukotrienes 1

Corticosteroids:

• Restrict to short courses for severe acute urticaria or angioedema affecting mouth 1
• Avoid long-term use except for delayed pressure urticaria or urticarial vasculitis 1

Prognosis: 50% of chronic urticaria patients clear by 6 months; those with weals plus angioedema have poorer outlook (>50% active after 5 years) 1

For Contact Dermatitis:

Immediate management:

• Strict avoidance of identified allergens (positive reactions including +/- doubtful reactions) 5
• Use hyporeactive products and strict adherence to "safe products list" 5
• Topical corticosteroids (appropriate potency for site/age) 6
• Soap substitutes and emollients liberally 6

Consider topical tacrolimus where topical steroids unsuitable or ineffective 3

Resistant cases:

• PUVA therapy for chronic hand eczema 3
• Alitretinoin for severe chronic hand eczema 3
• Consider azathioprine or ciclosporin 6

Follow-up at 3 months with both patient-reported and clinician-reported outcome measures to guide further therapy 5

Critical Pitfalls to Avoid

1. Don't assume urticaria is allergic - most chronic urticaria is idiopathic or autoimmune, not allergic 1
2. Don't order extensive laboratory panels for urticaria with normal examination (low yield) 2
3. Don't rely on clinical appearance alone to distinguish contact dermatitis types - patch testing is essential 3
4. Don't miss ACE inhibitor-induced angioedema - ask about all medications in angioedema without weals 4
5. Don't forget renal/hepatic dose adjustments for antihistamines in impaired patients 1
6. Avoid antihistamines in first trimester pregnancy when possible; chlorphenamine has longest safety record if needed 1